| 摘要 |
The present application describes novel uracil derivatives of formula I: A-W-U-X-Y-Z-U<a>-X<a>-Y<a>-Z<a> or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, W, U, X, Y, Z, U<a>, X<a>, Y<a>, and Z<a> are defined in the present specification, which are useful as inhibitors of TNF-alpha converting enzyme (TACE), matrix metalloproteinases (MMP), aggrecanase or a combination thereof. |
